Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec;10(24):1417.
doi: 10.21037/atm-2022-55.

Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients

María González-Cao  1 , Rafael Rosell  2
Affiliations
Editorial

Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients

María González-Cao et al. Ann Transl Med. 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-2022-55/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Chang E, Pelosof L, Lemery S, et al. Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. Oncologist 2021;26:e1786-99. 10.1002/onco.13887 - DOI - PMC - PubMed
    1. Zhu Y, Liu J. The Role of Neoantigens in Cancer Immunotherapy. Front Oncol 2021;11:682325. 10.3389/fonc.2021.682325 - DOI - PMC - PubMed
    1. Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell 2020;183:347-362.e24. 10.1016/j.cell.2020.08.053 - DOI - PubMed
    1. Chong C, Coukos G, Bassani-Sternberg M. Identification of tumor antigens with immunopeptidomics. Nat Biotechnol 2022;40:175-88. 10.1038/s41587-021-01038-8 - DOI - PubMed
    1. Moore TV, Nishimura MI. Improved MHC II epitope prediction - a step towards personalized medicine. Nat Rev Clin Oncol 2020;17:71-2. 10.1038/s41571-019-0315-0 - DOI - PMC - PubMed